HK Stock Market Move | Innovative drug concept stocks rose across the board today with the release of the National Medical Products Administration's annual report on new drug clinical trials. New policies support foreign investment in the pharmaceutical industry.

Concept stocks of innovative drugs rose across the board today. As of press time, SSY GROUP (02005) rose by 6.93% to HKD 2.16; KEYMED BIO-B (02162) rose by 4.14% to HKD 59.05; Jiangsu Hengrui Pharmaceuticals (01276) rose by 3.55% to HKD 56.9; AKESO (09926) rose by 2.23% to HKD 84.8; INNOVENT BIO (01801) rose by 1.86% to HKD 76.75. On the news front, on June 22, the National Medical Products Administration released the "Annual Report on the Progress of Clinical Trials for New Drug Registration in China by 2025," showing that the total number of clinical trials in China exceeded 5,000 for the first time, reaching a historical high. The report includes two main categories: new drug clinical trials and bioequivalence trials, with 2997 new drug clinical trials, accounting for 57.5% and a year-on-year increase of 18%; and 2218 bioequivalence trials, accounting for 42.5%. In addition, the Ministry of Commerce, the National Development and Reform Commission, and the Ministry of Finance issued 15 new policies to stabilize foreign investment, proposing to support foreign investment in the high-quality development of industries such as medicine. They are rushing to research and introduce detailed rules for segmented production of drugs to facilitate the overseas listing holders of drug market authorization to carry out segmented production of biological products and chemical drugs across borders. They are also speeding up the research and approval process to further expand the opening-up pilot areas for the field of bio-technology and wholly foreign-owned hospitals by foreigners. They are supporting insurance companies to include more innovative medical devices in commercial insurance coverage and continuously encouraging high-quality innovative medical devices to enter the Chinese market. They are building industry collaboration platforms to facilitate the entry of drugs produced by foreign enterprises into drug retail channels.